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High-density lipoproteins (HDLs) are considered anti-athero-
genic because they mediate peripheral cell cholesterol transport to
the liver for excretion and degradation. An important step in this
reverse cholesterol-transport pathway is the uptake of cellular
cholesterol by a specific subclass of small, lipid-poor apo-
lipoprotein A-I particles designated preb-HDL. The two
lipid-transfer proteins present in human plasma, cholesteryl ester
transfer protein (CETP) and phospholipid transfer protein
(PLTP), have both been implicated in the formation of preb-
HDL. In order to investigate the relative contribution of each of
these proteins, we used transgenic mouse models. Comparisons
were made between human CETP transgenic mice (huCETPtg),
human PLTP transgenic mice (huPLTPtg) and mice transgenic
for both lipid-transfer proteins (huCETPtg}huPLTPtg). These
INTRODUCTION
Plasma levels of high-density lipoprotein (HDL) cholesterol
correlate negatively with the risk of coronary artery disease, and
raising HDL cholesterol levels by drug treatment results in
prevention of coronary artery disease [1–4]. HDL is considered
to protect against atherosclerosis via its role in reverse cholesterol
transport [5]. This pathway involves the uptake of choles-
terol from peripheral cells and subsequent transport and delivery
to the liver for degradation and excretion. Recent data indicate
that the ATP-binding cassette transporter A1 (ABCA1) plays a
key role in the efflux of cholesterol from cells [6–8]. Patients suffer-
ing from Tangier disease, with a mutated form of the ABCA1
gene, show premature atherosclerosis, providing compelling
evidence for a substantial protective role of reverse cholesterol
transport in the development of atherosclerosis. The initial extra-
cellular acceptor of cellular cholesterol is a specific subclass of
HDL, designated preb-HDL [9]. Cellular cholesterol taken up
by preb-HDL is subsequently esterified by the action of
lecithin:cholesterol acyltransferase (LCAT). As a consequence,
preb-HDL matures into a-HDL. Esterified cholesterol from
a-HDL can be taken up in the liver either directly by selective
uptake or indirectly via low-density lipoproteins (LDLs). The
indirect pathway follows transfer of cholesteryl esters to very-
low-density lipoproteins (VLDLs) and LDLs by cholesteryl ester
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animals showed elevated plasma levels of CETP activity, PLTP
activity or both activities, respectively. We evaluated the gen-
eration of preb-HDL in mouse plasma by immunoblotting and
crossed immuno-electrophoresis. Generation of preb-HDL was
equal in huCETPtg and wild-type mice. In contrast, in huPLTPtg
and huCETPtg}huPLTPtg mice, preb-HDL generation was
3-fold higher than in plasma from either wild-type or huCETPtg
mice. Our findings demonstrate that, of the two plasma lipid-
transfer proteins, PLTP rather than CETP is responsible for the
generation of preb-HDL. These data support the hypothesis of a
role for PLTP in the initial stage of reverse cholesterol transport.
Key words: apoA-I, LCAT, lecithin:cholesterol acyltransferase,
reverse cholesterol transport, transgenic mice.
transfer protein (CETP) [9,10]. Thus preb-HDL is a key factor
in reverse cholesterol transport.
Although the plasma lipid-transfer proteins phospholipid
transfer protein (PLTP) and CETP have non-overlapping func-
tions [11], studies both in itro and in io have demonstrated
that CETP and PLTP may both contribute to the formation of
preb-HDL [12–18].
PLTP is involved in the transfer of phospholipids between
lipoproteins and in the remodelling of HDL [19–21]. Its physio-
logical function has been studied in several mouse models
[12,22–24]. PLTP-deficient mice show an impaired transfer of
post-lipolytic VLDL surface remnant phospholipids to HDL
and, as a consequence, decreased plasma HDL levels [21]. In
PLTP transgenic mice with slightly elevated PLTP activity levels
minor effects on plasma lipids and lipoprotein patterns were
found [15,23]. However, in double-transgenic mice expressing
both PLTP and human apolipoprotein A-I (apoA-I), preb-HDL
levels were increased [23]. We generated transgenic human PLTP
mice that show a moderate, though substantial overexpression of
PLTP (2.5–3-fold in hemizygous transgenic mice) [12]. Plasma
from these mice has an increased ability to generate preb-HDL
and prevents cholesterol accumulation in macrophages to a
greater extent than plasma from wild-type animals. From these
studies, we concluded that PLTP could have anti-atherogenic
properties via its ability to generate preb-HDL.
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Both CETP and PLTP belong to a family of lipid-transfer}
lipopolysaccharide-binding proteins [10,25]. Although CETP has
profound effects on lipoprotein metabolism in humans, some
species, including mice, lack CETP activity [26]. In itro studies
demonstrate that CETP transfers cholesteryl esters from HDL to
apoB-containing lipoproteins in exchange for triglycerides,
whereas PLTP does not transfer neutral lipids [5]. In addition to
PLTP, CETP is able to transfer phospholipids in itro, but it is
unknown whether they share this ability in io.
In the present study we evaluated the relative contributions of
CETP and PLTP to the formation of preb-HDL. To this end, we
made comparisons between various lines of transgenic mice
expressing human CETP, human PLTP or both lipid-transfer
proteins.
MATERIALS AND METHODS
Breeding and treatment of transgenic mice
Human CETP transgenic mice (line 5203; huCETPtg) were
kindly donated by Dr A. R. Tall (Columbia University, New
York, NY, U.S.A.) [27] and have a C57BL}6 background.
Human PLTP transgenic mice (huPLTPtg) were generated as
described previously [12] and were backcrossed to the C57BL}6
background for at least seven generations. Mice expressing the
human CETP and PLTP transgenes (huCETPtg}huPLTPtg)
were obtained by crossbreeding huCETPtg and huPLTPtg mice.
Both transgenes had the natural flanking sequences, including the
autologous promoters. Animals were housed in a temperature-
controlled room operating under a 12 h:12 h light}dark cycle.
Animals were fed regular chow and water ad libitum.
Blood samples were collected, from animals that had been
fasted overnight, from the orbital plexus by using Vitrex4
sodium-heparinized micropipettes (80 i.u. ; Modulohm A}S,
Copenhagen, Denmark) and were immediately stored on ice.
Blood was centrifuged at 1500 g
max
for 15 min at 4 °C. Plasma
was either used directly or stored in small aliquots at fi80 °C
before analysis. All animal experiments were done in compliance
with the Guidelines of the Ethical Committee on the Use of
Laboratory Animals of the Erasmus University Rotterdam
(protocol no. 120.99.05) and with the European Committee
Standards on the care and use of laboratory animals (Ministry of
Welfare, Health and Cultural Affairs, The Netherlands).
DNA analysis
Genomic DNA was isolated from tail clips of 10 day-old mice
and analysed for the presence of the huCETP transgene and}or
huPLTP transgene by PCR analysis. Conditions and primers
were as follows: huCETP, sense primer, 5«-CACTAGCCC-
AGAGAGAGGAGTGC-3«, antisense primer 5«- CTGAGCC-
CAGCCGCACACTAAC-3«, 28 cycles (94 °C, 1 min; 65 °C,
1 min; 72 °C, 1.5 min) ; huPLTP, sense primer, 5«-GCCACA-
GCAGGAGCTGATGC-3«, antisense primer, 5«-GCGGATGG-
ACACACCCTCAGC-3«, 28 cycles (94 °C, 1 min; 65 °C, 1 min;
72 °C, 2 min).
Plasma activity assays
CETP and PLTP assays were performed according to Speijer et
al. [28]. CETP activity was determined by measuring the rate of
transfer}exchange of radiolabelled cholesteryl oleate between
exogeneously added human LDL and HDL. PLTP activity was
determined bymeasuring the transfer of radiolabelled dipalmitoyl
phosphatidylcholine (DPPC) from liposomes †composed of
egg lecithin (Amersham, Little Chalfont, Bucks., U.K.) and
[$H]DPPC as a tracer· to exogenously added human HDL
(density, 1.063 g}ml! d! 1.21 g}ml). CETP and PLTP activi-
ties are expressed as a percentage of the human reference plasma:
100% is equivalent to the following activities ; CETP,
215.6 nmol}ml per h; PLTP, 13.9 lmol}ml per h.
Hepatic lipase activity was measured as described by Jansen et
al. [29]. LCAT activity was determined by measuring the for-
mation of radiolabelled cholesteryl ester after addition of 10 or
20 ll of mouse plasma to excess heat-inactivated plasma con-
taining [$H]cholesterol (Amersham) [30]. Hepatic lipase and
LCAT activities are expressed as a percentage of plasma from
wild-type mice (C57BL}6).
Quantification of plasma lipids and apolipoproteins
Plasma lipids were determined enzymically with commercially
available kits : total cholesterol with the F-chol kit of Boehringer
Mannheim (Mannheim, Germany) after hydrolysis of cholesteryl
esters with cholesterol esterase from Candida cylindracea (Boeh-
ringer Mannheim). Phospholipids were measured with the
PAP150 kit from BioMe! rieux (Lyon, France). Plasma tri-
glycerides were measured with the Sigma GPO-Trinder kit
(procedure no. 337-B; Sigma, St. Louis, MO, U.S.A.). Mouse
apoA-I was quantified by sandwich ELISA as reported in [12].
Gel-filtration chromatography of mouse plasma lipoproteins
Lipoprotein profiles were determined by gel filtration of freshly
isolated plasma on two HR10}30 FPLC columns in tandem
(Superose 6 prepgrade and Superdex 200 prepgrade; Pharmacia
Biotech, Uppsala, Sweden). The columns were equilibrated with
2 mM NaH
#
PO
%
}Na
#
HPO
%
, pH 7.4, containing 0.9% NaCl
(w}v), 0.02% NaN
$
(w}v) and 5 mM EDTA. Combined plasma
samples from four to seven mice were passed through 0.45 lm
filters from Millipore S. A. (Molsheim, France), and 0.5 ml were
subjected to gel filtration. The columns were run at 4 °C with a
flow rate of 0.1 ml}min. Fractions of 0.8 ml were collected.
Recoveries were " 90% for all analyses.
Quantification of preb-HDL
Mouse plasma samples were either frozen directly or incubated
in the presence of iodoacetate in order to measure preb-HDL
formation. Incubation conditions were as reported in [12]. Plasma
samples were separated by agarose-gel electrophoresis under
non-reducing, non-denaturing conditions and low ionic strength
according to the manufacturer’s instructions (Paragon Lipo
system; Beckman, Fullerton, CA, U.S.A.) to separate preb- and
a-migrating HDL. Proteins were transferred by capillary blotting
to nitrocellulose membranes (Schleicher & Schuell NY 13N
6214}95, Dassel, Germany). Membranes were blocked for 1 h in
5% (w}v) skimmed milk in 20 mM Tris}HCl, pH 7.4}0.5 M
NaCl. Membranes were subsequently incubated with an
affinity-purified rabbit anti-mouse apoA-I polyclonal antibody.
"#&I-Labelled donkey anti-rabbit F(ab«)
#
fragment (17 Ci}g;
Amersham) was used as the detection antibody. The relative
abundance of apo-AI among the a- or preb-HDL species was
calculated by quantitative scanning using a PhosphorImager
(GS-363; BioRad). Crossed immuno-electrophoresis was per-
formed as described in [12].
Statistical analysis
Data are expressed as means‡S.D. Differences between two
genotypes were analysed by two-sample Wilcoxon rank-sum
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tests. Differences between three genotypes were analysed by
ANOVA followed by Bonferroni correction.
RESULTS
Plasma activities of CETP and PLTP
CETP activities were measured in plasma from huCETPtg mice
and huCETPtg}huPLTPtg mice (Figure 1A). CETP activity in
wild-type mice was virtually absent (! 4% of human reference
Figure 1 Plasma CETP and PLTP activities in transgenic mice
Plasma activities were determined in individual plasma samples from huCETPtg mice (n fl 12)
and huCETPtg/huPLTPtg mice (n fl 10). Values are expressed as a percentage of human
reference plasma (means‡S.D.). (A) CETP activity : 100% human reference plasma is
equivalent to CETP activity of 215.6 nmol/ml per h ; *P ! 0.01 compared with huCETPtg mice
(rank-sum test). (B) PLTP activity : 100% human reference plasma is equivalent to PLTP activity
of 13.9 lmol/ml per h ; **P ! 0.0001 compared with huCETPtg mice (rank-sum test).
Figure 2 Plasma hepatic lipase and LCAT activities in transgenic mice
Plasma activities were measured in individual plasma samples from wild-type mice
(wt ; n fl 16), huCETPtg mice (n fl 12), huPLTPtg mice (n fl 8) and huCETPtg/huPLTPtg mice
(n fl 10). Values are means‡S.D. and are expressed as a percentage of the wild-type value.
(A) Hepatic lipase activity : 100% hepatic lipase activity of the wild-type is equivalent to
56.1 nmol/ml per h ; *P ! 0.05, significantly different from huCETPtg mice (ANOVA followed
by Bonferroni correction). (B) LCAT activity : 100% LCAT activity of the wild-type is equivalent
to 71.3 nmol/ml per h. Transgenic mice showed similar LCAT activities (not significantly
different).
Figure 3 Lipoprotein profiles of plasma from transgenic mice
Equal amounts of plasma from either huCETPtg mice (n fl 4) or huCETPtg/huPLTPtg mice
(n fl 7) were pooled and subjected to gel filtration on Superose 6 and Superdex 200 columns
connected in tandem as described in the Materials and methods section. Fractions were
analysed for (A) cholesterol, (B) phospholipids, (C) CETP activity and (D) PLTP activity.
Fractions 1–4 contain VLDL, 5–10 contain LDL, 11–19 contain HDL and 20–25 contain
lysophosphatidylcholine bound to albumin.
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Figure 4 HDL subfractions of incubated plasma samples from transgenic
mice
Analysis of HDL subfractions was performed in plasma from huCETPtg (lane 1),
huCETPtg/huPLTPtg (lane 2), huPLTPtg (lane 3) and wild-type (lane 4) mice. Mouse plasma
(10 ll) was incubated in the presence of an LCAT inhibitor (1 mM iodoacetic acid) at 37 °C
for 3 h. Equal amounts of plasma were run on a 0.5% agarose gel, transferred to nitrocellulose
membranes and subjected to immunoblotting using rabbit anti-mouse apoA-I IgG.
plasma). HuCETPtg mice had a CETP activity of 144‡34% of
human reference plasma whereas CETP activity in huCETPtg}
huPLTPtg mice was about 20% lower (P! 0.01).
PLTP activity levels were measured in plasma samples of
huCETPtg mice and huCETPtg}huPLTPtg mice (Figure 1B).
The PLTP activity in plasma of huCETPtg mice was somewhat
higher than human PLTP activity levels : 136‡16% of human
reference plasma, which is in agreement with measurements in
wild-type mice [12]. The PLTP activity in the huCETPtg}
huPLTPtg mice was 4-fold higher (Figure 1B). This activity level
closely resembles the level reported previously for huPLTPtg
mice [12].
Plasma hepatic lipase activity and LCAT activity
Mice express hepatic lipase activity in plasma, even without
intravenous injection of heparin [31]. We investigated whether
any differences in the activity of hepatic lipase in plasma between
huCETPtg mice and huCETPtg}huPLTPtg mice could be ob-
served. As shown in Figure 2(A), the huCETPtg}huPLTPtg mice
had lower levels of hepatic lipase activity than huCETPtg
mice (P! 0.05). Hepatic lipase activity in the huPLTPtg mice
was 91‡27% of wild-type mouse plasma.
In plasma, preb-HDL matures into a-HDL by the action of
LCAT. The levels of LCAT activity were not significantly
different between the three tested genotypes (Figure 2B).
Lipid and lipoprotein analysis
Plasma samples from either huCETPtg or huCETPtg}huPLTPtg
animals were analysed by gel-filtration chromatography to ex-
amine their lipoprotein profiles. Cholesterol and phospholipid
contents as well as CETP and PLTP activities were determined
in all fractions (Figure 3). In unfractionated plasma, huCETPtg}
huPLTPtg mice had lower levels of plasma cholesterol
than huCETPtg mice (1.09‡0.15 mM, nfl 9, versus 1.43‡
0.16 mM, nfl 11; P! 0.01), whereas triglyceride levels were
Figure 5 Crossed immuno-electrophoresis of incubated plasma samples
from transgenic mice
Plasma samples from transgenic mice were incubated as described in the legend of Figure 4
and in the Materials and methods section. Subsequently, 5 ll aliquots were applied to agarose
gels for the first dimension, followed by electrophoresis into an anti-mouse apoA-I-
containing gel for the second dimension. (A) Wild-type mice, (B) huCETPtg mice, (C)
huPLTPtg mice and (D) huCETPtg/huPLTPtg mice.
similar (huCETPtg mice, 0.38‡0.14, nfl 5; huCETPtg}
huPLTPtg mice, 0.48‡0.25, nfl 5, not statistically significant).
As evident from Figure 3(A), which shows the cholesterol profile,
this is due to a decrease in HDL cholesterol. The phospholipids
have a similar profile, showing a decrease in HDL phospho-
lipids due to PLTP overexpression (Figure 3B). The
phospholipids present in fractions 20–25 represent lysophospha-
tidylcholine bound to albumin. In both groups of mice CETP
activity eluted in fractions 14–18, corresponding to the position
of HDL particles (Figure 3C). PLTP activity eluted in fractions
11–15, the position of relatively large HDLs (Figure 3D), a
situation also found in humans.
Effects of huPLTP and huCETP expression on preb-HDL formation
To investigate the formation of preb-HDL, incubated plasma
samples from wild-type, huCETPtg, huPLTPtg and huCETPtg}
huPLTPtg mice were subjected to agarose-gel electrophoresis
followed by immunoblotting. Upon incubation, the levels of
preb-HDL increased in mice expressing human PLTP, whereas
neither wild-type nor huCETPtg mice showed appreciable levels
of preb-HDL formation (Figure 4). In order to quantify preb-
HDL formation, crossed immuno-electrophoresis experiments
were performed (Figure 5). The results corroborated the find-
ings from the immunoblotting experiments, since incubated
samples from mice expressing human PLTP showed relatively
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Table 1 Preb-HDL levels in plasma of transgenic mice
Plasma samples were incubated as described in the legend of Figure 4. Values represent the relative and absolute amounts of preb-HDL in plasma before and after incubation at 37 °C for 3 h.
These were calculated, as described in the legend of Figure 6, from the percentage of apoA-I present in preb-HDL and the total plasma apoA-I concentrations respectively. Values are means‡S.D.
(n fl 3).
Genotype Total plasma apoA-I (mg/ml)
Relative preb-HDL (% of plasma apoA-I) Absolute preb-HDL (lg of apoA-I/ml)
Pre-incubation Post-incubation Pre-incubation Post-incubation
Wild-type 1.0‡0.07 3.7‡0.9 7.3‡0.5 36.7‡12.1 73.5‡10.2
huCETPtg 0.88‡0.05 5.0‡0.8 7.3‡0.5 44.1‡10.9 64.5‡8.6
huPLTPtg 0.73‡0.24 6.0‡0.8 16.7‡0.9* 44.2‡14.8 125.1‡49.4*
huCETPtg/huPLTPtg 0.7‡0.09 7.3‡1.7 17.3‡1.3* 52.3‡20.2 121.2‡22.7*
* Significantly different from wild-type mice, P ! 0.05 (rank-sum test).
Figure 6 Preb-HDL formation in plasma samples from transgenic mice
Plasma samples from wild-type, huCETPtg, huPLTPtg and huCETPtg/huPLTPtg mice were
incubated as described in the legend of Figure 4. Values represent the differences in the relative
amounts of preb-HDL, expressed as a percentage of total plasma apoA-I, before and after
incubation. These were calculated based on the areas underneath the peaks of preb-HDL and
a-HDL following crossed immuno-electrophoresis. Values are means‡S.D. ; *P ! 0.001
compared with both wild-type and huCETPtg mice (ANOVA followed by Bonferroni correction).
higher preb-HDL peaks. Measurements of preb-HDL in plasma
without incubation revealed no significant differences between the
genotypes tested (Table 1). However, in incubated samples, sig-
nificant differences were observed in both relative and absolute
concentrations of preb-HDL between huPLTPtg mice on the one
hand and wild-type or huCETPtg mice on the other (Table 1).
Using the data in Table 1, the formation of preb-HDL during
incubation of plasma was calculated (see Figure 6). Preb-HDL
formation in plasma from huCETPtg}huPLTPtg and huPLTPtg
mice was at least 3-fold higher than in plasma from wild-
type mice and huCETPtg mice. Thus CETP does not seem to
make a substantial contribution towards the formation of
preb-HDL.
DISCUSSION
CETP and PLTP are important factors in modulating plasma
lipid transport and both have been implicated in the generation
of preb-HDL particles [12,13,15,16,18]. However, to date their
relative importance in this process has not been established
unequivocally. This is due to the fact that all available data
originate from studies in which only one of the lipid-transfer
proteins was investigated. Besides, the use of different models,
either in io or in itro, as well as the use of different techniques,
hampers a comparative evaluation. For this reason we have used
transgenic mouse models with relatively modest overexpression
of the human PLTP and}or CETP proteins, enabling us to make
direct comparisons of preb-HDL formation.
The huPLTPtg mice that we used as the parental strain to
generate huPLTPtg}huCETPtg mice have been described pre-
viously [12]. These mice have approx. 3-fold higher plasma
PLTP activity levels than wild-type mice. This results in more
pronounced effects on plasma lipids compared with those re-
ported by other groups using transgenic mice with low levels
of PLTP expression [15,23]. Strong overexpression, as found in
mice expressing human PLTP after transfection with adenoviral
constructs, was avoided since this causes extreme effects on
lipoprotein metabolism, resulting in a near absence of plasma
cholesterol [22,24].
The huCETPtg mice that were used in the present study were
created and characterized by Jiang et al. [27]. In addition to a
human CETP mini-gene, these mice have the natural flanking
DNA sequences of the human CETP gene (3.2 kb upstream
and 2.0 kb downstream sequences). This construct results
in CETP plasma activity levels that are much lower than other
CETP-overexpression models [32,33]. Moderate expression
of CETP in the huCETPtg mice used in the present study was
confirmed by measuring CETP mass by ELISA. Concentrations
ranged from 2.7 to 4.1 lg}ml in plasma samples from huCETPtg
mice (T. van Gent, J. T. Lie and A. van Tol, unpublished work),
which is about 1.5-fold higher than values found in human plasma
[34]. Thus this mouse model shows modest CETP expression
and resembles the human condition in terms of plasma CETP
activity and mass. In both models, expression of the transgene
resulted in distinct effects on plasma lipids}lipoproteins.
In order to evaluate possible interactions between the two
lipid-transfer proteins, in terms of either their respective transfer
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activities or the formation of preb-HDL, we extended our studies
with double-transgenic animals, huCETPtg}huPLTPtg mice.
This model resembles the situation in humans since, in contrast
to mice, humans express both plasma transfer proteins.
huCETPtg and huCETPtg}huPLTPtg mice showed a small
difference in plasma CETP activity levels. The expression of the
human PLTP gene is associated with a decrease in CETP activity
of about 20%. This decrease is confirmed on analysis of the
CETP activity profiles after gel filtration (Figure 3C). This effect
could be the result of a direct effect of overexpression of human
PLTP on the level of expression of the CETP transgene. An
alternative explanation is that PLTP expression causes a lower
plasma HDL concentration. Since HDL is the carrier of CETP,
this could eventually result in a decrease in CETP levels. The
profiles show that CETP activity elutes at a position corre-
sponding to that of HDL particles.
PLTP activity measured in huCETPtg}huPLTPtg mice equals
the PLTP activity in the huPLTPtg mice described previously
[12]. PLTP activity in huCETPtg mice was comparable with that
in wild-type mice. Therefore CETP does not seem to affect the
activity of the endogenous mouse PLTP in plasma. In comparison
with the lipoprotein profile found in huPLTPtg mice [12],
huCETPtg}huPLTPtg mice have somewhat smaller HDLs,
which is in agreement with previous studies in transgenic mice
expressing human CETP [35]. The activity profiles of PLTP in
huCETPtg mice and huCETPtg}huPLTPtg mice were measured
after gel filtration of plasma (Figure 3D). The profiles show that
PLTP activity elutes at the position corresponding to relatively
large-sized HDL particles in both groups of mice. Thus CETP
and PLTP co-elute with particles of different sizes, a situation
also found in humans [28].
The main purpose of the present study was to determine the
relative contribution of PLTP and CETP to preb-HDL gen-
eration. We evaluated the formation of preb-HDL in plasma
using two different methods and demonstrated that preb-HDL
formation is increased in plasma from transgenic mice expressing
human PLTP, whereas expression of human CETP did not affect
this process. These findings cannot be attributed to differences in
preference of the transfer proteins towards human versus mouse
HDL, since incubations of plasma from huCETPtg mice with
freshly isolated human HDL did not show formation of preb-
HDL (J. T. Lie, R. de Crom, M. Jauhiainen, T. van Gent, R. van
Haperen, L. M. Scheek,C. Ehnholmand A. van Tol, unpublished
work).
LCAT activity was similar in plasma of the various transgenic
mice, which implies that a difference in maturation of preb-HDL
into a-HDL is unlikely. Therefore differences in LCAT activity
cannot explain the observed distinctions in preb-HDL formation.
The involvement of hepatic lipase in the formation of preb-
HDL has been suggested [36]. In humans, virtually all hepatic
lipase is bound to liver endothelial cells, whereas in mice
hepatic lipase circulates in plasma [31]. It was therefore important
to know whether plasma from huCETPtg}huPLTPtg mice dis-
played higher hepatic lipase activity than plasma from huCETPtg
mice. Hepatic lipase activity was found to be lower in plasma
from huCETPtg}huPLTPtg compared with plasma from
huCETPtg mice, so this activity cannot explain the observed
differences in preb-HDL generation.
Other groups have reported a role for CETP in preb-HDL
formation [13,17,18]. Kunitake et al. [13] showed that preb-
HDL formation is stimulated by CETP in itro. Francone et al.
[18], using double-transgenic animals that overexpressed CETP
(driven by the metallothionein promoter) as well as human
apoA-I, observed increased levels of preb-HDL in these mice. In
the mouse models used here, CETP expression was driven by its
native promoter and CETP levels and activities were comparable
with those in human plasma. An increase in the generation of
relative and absolute plasma levels of preb-HDL formation was
only observed in huPLTPtg mice. Despite lower HDL concen-
trations in huCETPtg}huPLTPtg mice compared with
huCETPtg mice, plasma of huCETPtg}huPLTPtg mice had a
greater ability to produce preb-HDL. This finding of a com-
bination of low HDL cholesterol levels and increased preb-HDL
formation was also observed in huPLTPtg mice [12], as well as in
mice using adenoviral overexpression of PLTP [22,24].
Although CETP and PLTP share similar structural properties
and belong to the same gene family, it has been found that they
have non-overlapping functions in io [11]. The roles of the
HDL modulators CETP and PLTP in atherosclerosis have not
yet been elucidated. CETP participates in reverse cholesterol
transport, a function that may mean it has anti-atherogenic
potential [10]. On the other hand, CETP mediates the exchange
of cholesteryl esters in HDL for triglycerides in VLDL. This
process leads to a decrease in HDL cholesterol and to an increase
in potentially pro-atherogenic VLDL and LDL cholesterol [37].
Although substantial overexpression of human CETP was re-
ported to cause increased susceptibility to diet-induced athero-
sclerosis [32], CETP has been proved to be anti-atherogenic in
other (compound) transgenic mouse models [38,39]. In rats,
high-level expression of human CETP is highly atherogenic [33],
whereas in rabbits inhibition of CETP proved to be anti-
atherogenic [40]. The impact of CETP on atherosclerosis in
humans remains inconclusive [37]. The present study supports
the notion that PLTP, rather than CETP, is responsible for the
generation of preb-HDL.The impact of PLTP on diet-induced
atherosclerosis will be the subject of future investigations.
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